News

The staff neurologist at Cleveland Clinic's Mellen Center spoke about his clinical experience in switching patients from their current disease-modifying therapy to ocrelizumab.

With a pair of sBLAs under FDA review, the Allergan treatment may finally have an official indication for use in spasticity after years of off-label use by physicians.

Gharagozloo spoke about the early phase model of MS she and her colleagues developed to explore the use of Nlrx1, a mitochondria-located innate immune sensor, in CNS inflammation.

Study results suggest that no difference in outcomes of function, survival, fatigue, or quality of life are seen between those undergoing intensive or standard exercise regimens.

Eisai and Biogen have announced that the phase 3 ENGAGE and EMERGE trials, in addition to the PRIME phase 1b and EVOLVE phase 2 studies, of the monoclonal antibody, will be discontinued.

The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in OSA in once-daily 37.5 mg, 75 mg, and 150 mg doses.

The migraine specialist spoke to the CGRP receptor antagonist’s potential impact on patients with migraine who have been lacking a novel acute treatment for some time.

The postdoctoral scholar at the University of California, San Francisco, spoke about a prognostic marker that can be used to study the role of genetic, epidemiologic and immune variables on MS, and to measure the long-term impact of treatment in clinical trials.

This is the first and largest study that explored mortality associated with beta interferon for treatment of MS in the clinical setting.

The professor of neurology at Harvard Medical School spoke about the long-term correlations between neurofilament light chain and MS outcomes.

The multiple sclerosis specialist at Baylor Scott & White Health spoke about which symptoms present the biggest challenges for providers.

The Postdoctoral Scholar at the University of California San Francisco spoke about a longitudinal study that evaluated the utility of spinal cord atrophy measured from brain scans as a surrogate marker for impending conversion to secondary progressive MS.

Is there a connection between this patient’s ocular symptoms and migraines?

The voucher allows for an expedited 6-month review of the drug’s pending New Drug Application with the FDA.

The staff neurologist at Premier Neurology, a partner in care with the National MS Society, spoke about how to best overcome the challenges presented by the symptomatic management of MS.

Conversations in the hospital cafeteria.

The director of the Medstar Georgetown University Headache Center spoke about the data that’s been presented thus far, as well as how ubrogepant separates itself from what’s currently available for patients.

The staff neurologist at the Mellen Center shared the findings from a poster the group presented from the cohort of patients in which they evaluated quantitative MRI.

Understanding risk perception and risk tolerance can lead to greater satisfaction with treatment choices and adherence for patients with MS.

Neurology News Network for the week of March 16, 2019.

The staff neurologist at Cleveland Clinic's Mellen Center spoke about the real-world observational study of the primary-progressive MS treatment.

The neurologist with Premier Neurology spoke about the challenges and state of symptomatic care in multiple sclerosis.

EEG and brain MRI findings are normal-what do you suspect?

The research staff member at the IBM Research-Australia lab discussed how he and colleagues utilized machine learning to identify a set of proteins in blood that can predict the concentration of amyloid-beta in spinal fluid.

After almost a year on the market, post-marketing data has been suggestive of a risk of anaphylaxis and angioedema in patients who are hypersensitive to erenumab or the excipients.

Ned Sharpless, MD, the director of the National Cancer Institute, has been named to the position of acting FDA Commissioner. The announcement was made just a week after the current commissioner, Scott Gottlieb, MD, announced his plans to resign in early April.

The staff neurologist at Cleveland Clinic's Mellen Center spoke about re-examining patient-reported outcomes to better understand the quality of life of patients and how it can affect clinical care.

The 2-year safety and efficacy extension of the CHANGE-MS trial ultimately showed encouraging dose-dependent effects with the 18-mg/kg dose on confirmed 12-week EDSS and 25-foot timed walk scores.